Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-061267
Filing Date
2025-06-20
Accepted
2025-06-20 19:29:56
Documents
1
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2518583-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2518583-1_4seq1.xml 4 3801
  Complete submission text file 0001104659-25-061267.txt   5394
Mailing Address C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560
Business Address
Nolet Chris (Reporting) CIK: 0001782814 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41929 | Film No.: 251062687

Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Issuer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)